NCT06058689 is a Phase 1 clinical trial of Pomalidomide 4 MG Oral Capsule in Bioequivalence Study, sponsored by Megalabs.

Who is sponsoring NCT06058689?

NCT06058689 is sponsored by Megalabs.

What drugs are being tested in NCT06058689?

Interventions in NCT06058689: Pomalidomide 4 MG Oral Capsule.

What condition does NCT06058689 study?

NCT06058689 studies Bioequivalence Study.

Is NCT06058689 still recruiting?

NCT06058689 is currently status unknown. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT06058689

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Bioequivalence Study of Pomalidomide

Status unknown Phase 1 Last updated 28 September 2023

What this trial tests

Phase 1 trial testing Pomalidomide 4 MG Oral Capsule in Bioequivalence Study in 10 participants. Status unknown.

Timeline

15 September 2024

Primary endpoint
15 November 2024

15 March 2025

Quick facts

Lead sponsor	Megalabs
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	10
Start date	15 September 2024
Primary completion	15 November 2024
Estimated completion	15 March 2025
Sites	1 location across India

Drugs / interventions tested

Pomalidomide 4 MG Oral Capsule

Conditions studied

Bioequivalence Study — all drugs for Bioequivalence Study →

Sponsor

Megalabs — full company profile →

Who can join

Adults 18 to 45, male only, with Bioequivalence Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot bioequivalence trial of two pomalidomide formulations consisting in 4 mg oral capsules.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pomalidomide 4 MG Oral Capsule

Trials testing the same drug.

NCT03731832 — Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory · Phase 2 · completed
NCT03424928 — A Pilot Bioequivalence Study of Pomalidomide · Phase 1 · completed

Other Megalabs trials

Trials by the same sponsor.

NCT04958772 — Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers · Phase 1 · not yet recruiting
NCT06331715 — Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg · Phase 4 · completed
NCT04873765 — Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06058689 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Megalabs
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06058689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing